12:25am Wednesday 18 October 2017

Novel biomarker approach suggests new avenues to improve schizophrenia disease management

“These markers, possibly from as early as embryonic development or birth, could be of considerable clinical importance as they could allow for identification of distinct schizophrenia subtypes or help predict treatment responses,” said Karolina Aberg, Ph.D., associate director of the Center for Biomarker Research and Personalized Medicine and first author of the study.

Schizophrenia is a devastating psychiatric disorder. Although there is strong support for the involvement of DNA sequence variation in the development of the disorder, other factors such as environmental influences are also likely to play a major role.

The research team performed one of the first large-scale, methylome-wide association studies (MWAS) of schizophrenia, as detailed online in the January issue of JAMA Psychiatry, the JAMA Network journal.

“Methylation is a specific modification to the DNA molecule that could potentially reflect environmental events,” said Edwin van den Oord, Ph.D., director of the Center for Biomarker Research and Personalized Medicine and senior author of the study. “Therefore, DNA methylation studies are very promising complements to traditional genetic studies that potentially can give us a deeper understanding of the schizophrenia disease etiology.”

In this study, researchers investigated approximately 27 million DNA methylation markings in blood samples from 1,497 schizophrenia cases and controls.

This methylome-wide screening was performed by extracting the methylated portion of the genome and then investigating this portion with massively parallel next-generation sequencing. To ensure that the findings from this screening were not false findings caused, for example, by method-specific artifacts or statistical errors, researchers used a different technology to follow up the critical top findings in independent subjects who were not part of the initial screening step. 

The study identified 139 highly significant methylation sites. Many of the replicating markings could be linked to hypoxia, immune response and neuronal differentiation, which are risk factors previously associated with schizophrenia development.

Collaborating institutions included the Karolinska Institutet in Sweden and the University of North Carolina at Chapel Hill. The Broad Institute in Cambridge, Mass., prepared samples. Edge Bio in Gaithersburg, Md., performed the lab work for the methylome-wide assays.

The study was supported by the National Institute of Mental Health (grant #RC2MH089996, PI: Van den Oord).
About VCU and the VCU Medical Center

Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls nearly 31,000 students in 223 degree and certificate programs in the arts, sciences and humanities. Sixty-eight of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University comprise the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.
ReadyCam

News Directors: Broadcast access to VCU experts can be arranged through the university’s VideoLink ReadyCam studio. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact VCU University Public Affairs, (804) 828-1231.
VCU School of Pharmacy’s Center for Biomarker Research and Personalized Medicine has been in operation since 2006. Its mission is to develop and apply novel methods to identify and use biomarkers that will improve understanding of disease and tailor medication use in patients to enhance efficacy and minimize toxicity.

By Eric Peters
University Public Affairs
804-828-0563
petersem@vcu.edu


Share on:
or:

MORE FROM Schizophrenia

Health news